Blog
About

23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

      Cancer Cell

      Drug Resistance, Neoplasm, Fibroblast Growth Factors, antagonists & inhibitors, metabolism, Humans, Islets of Langerhans, pathology, Neovascularization, Pathologic, prevention & control, Pancreatic Neoplasms, physiology, blood supply, Receptors, Vascular Endothelial Growth Factor, Signal Transduction, Vascular Endothelial Growth Factor A, Cell Line, Tumor

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis. Inhibition of VEGFR2 but not VEGFR1 markedly disrupted angiogenic switching, persistent angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to VEGFR2 blockade emerged, as tumors regrew during treatment after an initial period of growth suppression. This resistance to VEGF blockade involves reactivation of tumor angiogenesis, independent of VEGF and associated with hypoxia-mediated induction of other proangiogenic factors, including members of the FGF family. These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition.

          Related collections

          Author and article information

          Journal
          16226705
          10.1016/j.ccr.2005.09.005

          Comments

          Comment on this article